Safety and efficacy of direct oral anticoagulants in comparison with warfarin across different BMI ranges: A systematic review and meta-analysis
Open Access
- 14 April 2022
- journal article
- review article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 77, 103610
Abstract
Ay 2021 on PubMed, Scopus and Embase databases. The data was extracted and pooled using a random effects model. Our study consisted of patients being treated for VTE and AF, across different BMI categories. For the comparison of DOAC, risk ratios (RR) with 95% confidence intervals (CIs) were used, whilst for the second comparison between warfarin and DOACs odds ratios (OR) were used. Results: In our first comparison, 12 studies (n = 254,908 patients) were included. For our second comparison, six studies (n = 109,609 patients) were included. Major bleeding events in the underweight group were higher than normal weight [RR: 1.89 (1.10, 3.23); P = 0.02; I2 = 0%]. Overweight patients were related with reduced rates of VTE than in patients with normal BMI [RR: 0.86 (0.76, 0.97); P = 0.02; I2 = 0%]. In comparison with patients receiving warfarin, DOACs had significantly reduced risk of major bleeding in normal weight, overweight and obese [OR: 0.64 (0.49, 0.83); P = 0.0007 I2 = 90%]. Conclusion: The risk of VTE reduces with an increasing BMI, hence there could be a possible obesity paradox in patients with anticoagulation therapy. In comparison to warfarin, DOACs proved to be the safer option by having a reduced risk of bleeding across all BMI categories. HIGHLIGHTS Warfarin therapy and its effectiveness for prevention of thromboembolism.Effect of warfarin and DOACs over different BMI ranges.Safety and efficacy of DOACs across different BMI ranges.Lower risk of bleeding in normal weight, overweight, and obese patients with DOACs.Warfarin and DOACs across different BMI categories in VTE and AF patients....Keywords
This publication has 49 references indexed in Scilit:
- N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial FibrillationJACC, 2013
- Association of Body Mass Index With Major Cardiovascular Events and With Mortality After Percutaneous Coronary InterventionCirculation: Cardiovascular Interventions, 2013
- Impact of Obesity on Drug Metabolism and Elimination in Adults and ChildrenClinical Pharmacokinetics, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationaleAmerican Heart Journal, 2010
- The role of the renin–angiotensin system in atrial fibrillation and the therapeutic effects of ACE‐Is and ARBSBritish Journal of Clinical Pharmacology, 2008
- Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on Atrial FibrillationEuropean Heart Journal, 2008
- Tumor necrosis factor-α alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytesLife Sciences, 2007
- Measuring inconsistency in meta-analysesBMJ, 2003
- Low body mass index is a risk factor forimpaired endothelium-dependent vasodilation in humans: role of nitric oxide and oxidative stressJACC, 2003